Jing Huang

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 25

Top Venues

Nature medicine

Cancer medicine

Thoracic cancer

Cancer communications (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Jing Gao, Yan Song, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Xiao Qi, Qingyu Wang, Jun Zhu, Jing Huang
The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis. Cancer medicine 13 (10) (2024)
Jing Gao, Yan Song, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Xiao Qi, Qingyu Wang, Jun Zhu, Jing Huang
The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis. Cancer medicine 13 (10) (2024)
Jing Gao, Yan Song, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Xiao Qi, Qingyu Wang, Jun Zhu, Jing Huang
The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis. Cancer medicine 13 (10) (2024)
Yan Song, Bo Zhang, Dao Xin, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Jing Li, Qingyu Wang, Jun Zhu, Jing Huang, null null
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nature medicine 29 (2) (2023)
Yan Song, Bo Zhang, Dao Xin, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Jing Li, Qingyu Wang, Jun Zhu, Jing Huang, null null
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nature medicine 29 (2) (2023)
Yan Song, Bo Zhang, Dao Xin, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Jing Li, Qingyu Wang, Jun Zhu, Jing Huang, null null
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nature medicine 29 (2) (2023)
Yan Song, Bo Zhang, Dao Xin, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Jing Li, Qingyu Wang, Jun Zhu, Jing Huang, null null
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nature medicine (2023)
Yan Song, Bo Zhang, Dao Xin, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Jing Li, Qingyu Wang, Jun Zhu, Jing Huang, null null
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nature medicine 29 (2) (2023)
Manish A Shah, Kohei Shitara, Jaffer A Ajani, Yung-Jue Bang, Peter Enzinger, David Ilson, Florian Lordick, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, Hwoei Fen Soo Hoo, Haci Mehmet Turk, Mok Oh, Jung Wook Park, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Rui-Hua Xu
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nature medicine (2023)
Yan Song, Bo Zhang, Dao Xin, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Jing Li, Qingyu Wang, Jun Zhu, Jing Huang, null null
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nature medicine 29 (2) (2023)
Dao Xin, Yan Song, Lan Mu, Bo Zhang, Ling Qi, Jing Gao, Xingyuan Wang, Jianping Xu, Tao Qu, Jing Huang
The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma. Thoracic cancer (2023)
Yan Song, Bo Zhang, Dao Xin, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Jing Li, Qingyu Wang, Jun Zhu, Jing Huang, null null
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nature medicine 29 (2) (2023)
Lin Wang, Yanrong Zhu, Bo Zhang, Xi Wang, Hongnan Mo, Yuchen Jiao, Jiachen Xu, Jing Huang
Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy. Thoracic cancer 13 (11) (2022)
Yang Zhang, Zi-Xian Wang, Lin Shen, Jin Li, Jing Huang, Wei-Guo Su, Dong-Sheng Zhang, Rui-Hua Xu
A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer. Cancer communications (London, England) (2022)
Jia-Lin Tang, Bo Zhang, Jian-Ping Xu, Ling Qi, Dao Xin, Lin Wang, Bing-Zhi Wang, Yan-Tao Tian, Yong Li, Jing Huang
Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer. Cancer medicine (2022)
Yan Song, Ning Li, Qun Li, Xinjun Liang, Shu Zhang, Qingxia Fan, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Xiaofei Wang, Yiwei Dou, Jing Huang
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. Journal for immunotherapy of cancer 8 (2) (2021)
Yan Song, Juxiang Xiao, Wentao Fang, Ping Lu, Qingxia Fan, Yongqian Shu, Jifeng Feng, Shu Zhang, Yi Ba, Yang Zhao, Ying Liu, Chunmei Bai, Yuxian Bai, Yong Tang, Jie He, Jing Huang
The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. Cancer biology & medicine (2021)
Jing Huang, Juxiang Xiao, Wentao Fang, Ping Lu, Qingxia Fan, Yongqian Shu, Jifeng Feng, Shu Zhang, Yi Ba, Yang Zhao, Ying Liu, Chunmei Bai, Yuxian Bai, Yong Tang, Yan Song, Jie He
Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial. Cancer medicine 10 (5) (2021)
Yun Liu, Bo Zhang, Jianping Xu, Xingyuan Wang, Jialin Tang, Jing Huang
Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma. Cancer chemotherapy and pharmacology 88 (3) (2021)
Bo Zhang, Jing Huang, Jialin Tang, Sheng Hu, Suxia Luo, Zhiguo Luo, Fuxiang Zhou, Shiyun Tan, Jieer Ying, Qing Chang, Rui Zhang, Chengyun Geng, Dawei Wu, Xiangyong Gu, Binlei Liu
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial. Journal for immunotherapy of cancer 9 (4) (2021)
Lan Mu, Yan Song, Kuaile Zhao, Ying Liu, Qingxia Fan, Xi Wang, Qun Li, Xiaopeng Wang, Jing Huang
SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study. Thoracic cancer 12 (9) (2021)
Bo Zhang, Ling Qi, Xi Wang, Jianping Xu, Yun Liu, Lan Mu, Xingyuan Wang, Lidan Bai, Jing Huang
Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer communications (London, England) 40 (12) (2020)
Xi Wang, Bo Zhang, Xuelian Chen, Hongnan Mo, Dawei Wu, Bo Lan, Qun Li, Binghe Xu, Jing Huang
Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody. Thoracic cancer 10 (6) (2019)
Jing Huang, Binghe Xu, Ying Liu, Junxing Huang, Ping Lu, Yi Ba, Lin Wu, Yuxian Bai, Shu Zhang, Jifeng Feng, Ying Cheng, Jie Li, Lu Wen, Xianglin Yuan, Changwu Ma, Chunhong Hu, Qingxia Fan, Xi Wang
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. Cancer communications (London, England) 39 (1) (2019)
Jing Huang, Hongnan Mo, Weilong Zhang, Xuelian Chen, Dong Qu, Xi Wang, Dawei Wu, Xingyuan Wang, Bo Lan, Beibei Yang, Pei Wang, Bo Zhang, Qing Yang, Yuchen Jiao, Binghe Xu
Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. Cancer 125 (5) (2018)

Jing Huang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jing Huang